Synapse Open Synapse
Biology

Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition

GEN · · 4 min read

Shionogi signaled its intent to focus on rare disease drugs in April when it acquired Radicava (edaravone), an amyotrophic lateral sclerosis (ALS) treatment, from Tanabe Pharma for $2.5 billion and potential royalties.

Latest from GEN